Hetero Healthcare R & D Centre had developed across a vast area. A striking feature of Hetero Healthcare is the well-planned and comprehensive infrastructure provided.
One of the world leaders in developing and manufacturing a wide range of brands/non-brands generics including Oncology and ARV drugs
Launched first generic 'COVIFOR' (Remdesivir) in India for the treatment of COVID-19 (licensing agreement with Gilead Sciences Inc.)
Basic manufacturer of Oseltamivir (sub-licensing agreement with Hoffman-La Rosche, Switzerland).
Click here for more...
When it comes to innovation in the development of new drugs and therapeutic biological products. our company is completely focused structuring the Molecule need of the industry Innovation Strategy.
We aim to improve the quality life of the people with our product line and along with a continuous Research and Development process. To be Recognized as an Innovative Pharmaceutical Company satisfying needs of the Customers, Doctors and Chemists.
Express pharma Excellence award is one of the most prestigious awards for the industry leading pharmaceutical companies. This year’s annual program was conducted on 20th August on E-platform.Read More
After Covifor Injection, Hetero developed the second drug 'Favipiravir' for treatment of mild to moderate Coronavirus symptoms following the approvals from the Drug Controller General of India (DCGI) to manufacture and market the generic drug undeRead More
Tips from Experts on GERD ManagementRead More
The third Annual International Award Ceremony was celebrated in Singapore by 275 people that included 125 qualifiers and their family members.Read More
A good smile while meeting a person is considered the best gesture. However, smiling, laughing, talking, and chewing food are done by a set of 32 sensory organs called teeth.Read More
The importance for safety facial masks has taken a spike since March 2020, due to the COVID-19 pandemic.Read More
Our Toll Free Number 18001034696
Copyright © 2021 All Rights Reserved by Hetero Healthcare Limited.